

ASX RELEASE**Board Update**

9 September 2025 – Global analytical science and device company Trajan Group Holdings Limited (**ASX: TRJ**) (**Trajan** or **the Company**) advises that Ms Sara Watts, Non-executive Director and Chair of the Audit and Risk Committee has notified the Board of her decision to retire from the Trajan Board of Directors and will not seek re-election at the 2025 Annual General Meeting (AGM).

As a result, Ms Watts' term as a Non-executive Director will cease at the conclusion of the AGM on 28 October 2025.

Ms Watts joined the Trajan Board in March 2021, just prior to the Company's IPO in June of that year. Ms Watts commented "It has been a privilege to work with my colleagues at Trajan over the past 4 years. The focus on using science and medical technology to improve human wellbeing is as strong today as it was at listing, and I wish everyone at Trajan much success as they pursue this goal".

Ms Tiffany Lewin will assume the role of ARC Chair while the Board will continue to monitor the composition of the Board and its Committees.

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited.

END

Contact:**Investors**

Alister Hodges
investorrelations@trajanscimed.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe